Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

PEG interferon and ribavirin reduce liver fibrosis rate in hepatitis C

A combination of pegylated interferon and ribavirin significantly reduces the rate of fibrosis progression in patients with hepatitis C, according to research published in the May issue of Gastroenterology.

News image

fiogf49gjkf04

A group of international researchers evaluated the effect of pegylated (PEG) interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Individual data from 3010 naive patients, with pretreatment and post-treatment biopsies from 4 randomized trials, were pooled.

Ten different regimens combining standard interferon, PEG interferon, and ribavirin were compared.

The impact of each regimen was estimated by the percentage of patients with at least one grade improvement in the necrosis and inflammation (METAVIR score).

It was also assessed by the percentage of patients with at least one stage worsening in fibrosis METAVIR score, and by the fibrosis progression rate per year.

Necrosis and inflammation improvement ranged from 39% (interferon, 24 weeks) to 73% (optimized PEG interferon and ribavirin).

Fibrosis worsening ranged from 23% (interferon, 24 weeks) to 8% (optimized PEG interferon and ribavirin).

The team found that all regimens significantly reduced the fibrosis progression rates in comparison to rates before treatment.

Furthermore, the reversal of cirrhosis was observed in 49% of 153 patients with baseline cirrhosis.

Necrosis and inflammation improved by 73% with PEG interferon and ribavirin.
Gastroenterology

Six factors were found to be independently associated with the absence of significant fibrosis after treatment.

These included baseline fibrosis stage (odds ratio [OR] = 0.12), sustained viral response (OR = 0.36), and age less than 40 years (OR = 0.51).

The other associated factors were body mass index less than 27 kg/m2 (OR = 0.65), no or minimal baseline activity (OR = 0.70), and viral load less than 3.5 millions copies per milliliter (OR = 0.79).

Professor Thierry Poynard, of the University of Paris VI, Paris, France, concluded on behalf of the group, "PEG-interferon and ribavirin combination significantly reduces the rate of fibrosis progression in patients with hepatitis C."

In an accompanying Editorial, Professor Michael J.P. Arthur, of Southampton General Hospital, England, comments, "The study of Poynard et al. challenges all of us to accept that the traditional view of cirrhosis as a progressive, irreversible disease is no longer correct.

"This augurs well for the future of our patients with chronic HCV infection, particularly if they clear the virus with treatment," he adds.

"The study also encourages further scientific investigation of the key cell and molecular mechanisms of liver fibrosis.

"It raises the prospect that an antifibrotic agent, aimed at promoting regression of disease, may be an important therapeutic strategy for the future," he concludes.

Gastroenterology 2002; 122(5): 1303-13
03 May 2002

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohnís disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohnís
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us